As patient-centric evidence continues to shape the future of drug development, challenges around increased complexity and regulatory scrutiny must be addressed.
Chris McSpiritt
Advertisement
Articles by Chris McSpiritt
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
2
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
3
Alnylam Announces $250 Million Investment in Massachusetts Facility
4
President Trump Announces Nine More TrumpRx Participants
5